Immunotherapeutic Advancements for Glioblastoma

Ampie, Leonel; Woolf, Eric C.; Dardis, Christopher

doi:10.3389/fonc.2015.00012

Cited by 42 publications

(38 citation statements)

References 83 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Proteomics 18, 1255Proteomics 18, -1268. ent cancers, including GBM, has drawn significant attention (3,4), reviewed in (5)(6)(7)(8)(9)(10)(11)(12)(13). Much of the recent excitement about cancer immunotherapy stems from the success in treating patients with immune checkpoint modulators, which induce anti-cancer T cell immune reactions that can break tolerance and bring about complete responses in increasingly larger percentages of patients (14,15).…”

mentioning

confidence: 99%

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Shraibman¹,

Barnea²,

Kadosh³

et al. 2018

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Furthermore, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.

show abstract

mentioning

confidence: 99%

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Shraibman¹,

Barnea²,

Kadosh³

et al. 2018

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is especially intriguing for brain tumor applications, because toxicities associated with traditional drugs pose significant problems for healthy brain tissue[124,125]. However, the presence of the BBB confounds most traditional immunotherapeutic approaches.…”

Section: Drug Deliverymentioning

confidence: 99%

Drug and gene delivery across the blood–brain barrier with focused ultrasound

Timbie

Mead

Price

2015

Journal of Controlled Release

169

125

View full text Add to dashboard Cite

The blood-brain barrier (BBB) remains one of the most significant limitations to treatments of central nervous system (CNS) disorders including brain tumors, neurodegenerative diseases and psychiatric disorders. It is now well-established that focused ultrasound (FUS) in conjunction with contrast agent microbubbles may be used to non-invasively and temporarily disrupt the BBB, allowing localized delivery of systemically administered therapeutic agents as large as 100 nm in size to the CNS. Importantly, recent technological advances now permit FUS application through the intact human skull, obviating the need for invasive and risky surgical procedures. When used in combination with magnetic resonance imaging, FUS may be applied precisely to pre-selected CNS targets. Indeed, FUS devices capable of sub-millimeter precision are currently in several clinical trials. FUS mediated BBB disruption has the potential to fundamentally change how CNS diseases are treated, unlocking potential for combinatorial treatments with nanotechnology, markedly increasing the efficacy of existing therapeutics that otherwise do not cross the BBB effectively, and permitting safe repeated treatments. This article comprehensively reviews recent studies on the targeted delivery of therapeutics into the CNS with FUS and offers perspectives on the future of this technology.

show abstract

“…Recently, studies on immunotherapy have provided a new perspective to effectively and safely treat some lethal tumors [11,12]. However, the molecular mechanism of the immunology in glioma still remains unclear, especially its immunogenomic effect [13]. At present, researchers can quickly identify crucial biomarkers for tumor monitoring and surveillance due to the development of gene expression databases.…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Value of Risk Score Based on Immunogenenomic Landscape Analysis in Glioma

Luo

Huang

Tao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Glioma is a lethal intracranial tumor, and inflammation plays an important role in the initiation and development of glioma. Hence, there is an urgent need to conduct a bioinformatics analysis of immune-related genes (IRGs) for glioma. The present study aims to explore the association of the risk score with clinical outcomes and predict the prognosis with glioma. Methods: In The Cancer Genome Atlas (TCGA) database, 462 low grade glioma (LGG) samples and 166 glioblastoma (GBM) samples were reviewed, and IRGs correlated with the prognosis were selected by performing a survival analysis and establishing a Cox regression model. The potential molecular mechanism of these IRGs were also explored with assistance of computational biology. The risk score based on seven survival-associated IRGs was determined with the help of the multivariable Cox analysis, the patients were divided into two subgroups according to their risk score. Results: It was found that these differentially expressed IRGs were involved with the cytokine-cytokine receptor through functional enrichment analysis. The risk score based on the seven IRGs (SSTR5、CXCL10、CCL13、SAA1、CCL21、CCL27 and HTR1A) performed well in predicting patient’s the overall survival (OS), and correlated with age, 1p/19q codeletion status, IDH status, and WHO grades, both in the training (TCGA) datasets and the validation ((Chinese Glioma Genome Atlas) CGGA) datasets. The risk score also could reflect infiltration through several types of immune cells. Conclusions: This present study screened some IRGs associated with the patient’s clinical characteristic and prognosis, connect to the immune repertoire, demonstrated the importance of the risk score as a promising biomarker for estimating the clinical prognosis of glioma.

show abstract

Immunotherapeutic Advancements for Glioblastoma

Cited by 42 publications

References 83 publications

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Drug and gene delivery across the blood–brain barrier with focused ultrasound

The Prognostic Value of Risk Score Based on Immunogenenomic Landscape Analysis in Glioma

Contact Info

Product

Resources

About